Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma

Lists of Inclusion and Exclusion criteria: * Patients must have histologically confirmed hepatocellular carcinoma * Patients must have measurable disease by CT scan * Have not received previous palliative systemic chemotherapy for metastatic disease. (Adjuvant chemotherapy or radiation therapy for non target lesion can be allowed.) * Patients progress after previous local treatment and at the time of randomization is at least 4 weeks after the last interventional therapy (Hepatic Artery Infusion, Trans-Artery Embolization or Trans-Artery Chemo-Embolization) or at least 4 weeks after the last radiotherapy/ablation/ Percutaneous Ethanol Injection to the target lesion. * WHO 0-2 grades (Karnofsky Performance Score ≥ 70) * Patients must have adequate organ and marrow function: * Neutrophilus ≥ 1.5 x 10\^9/L * Platelets ≥ 75 x 10\^9/L * Asparagine AminoTransferase, Alanine AminoTransferase \< 2.5 x Upper Normal Limit(UNL) * Total Bilirubin ≤ 1.5 x UNL * International Normalized Ratio \< 1.5 * Child stage A or B * Creatinine ≤ 1.5 X UNL Exclusion Criteria: * Documented allergy to platinum compound or to other study drugs. * Active Gastro-Intestinal bleeding and active haematologic malignancy * Previous liver transplantation. * Patients concomitantly receiving any other anti-cancer therapy. * Patients who are receiving any other study treatments. * Pregnant or lactating women or women of childbearing potential without proper contraceptive methods. * History of other malignant diseases, except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix. * Central nervous system metastasis * Other serious illness or medical conditions * Neuropathy ≥ grade 2 The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.